The H. pylori antigen qualitative test detects the presence of Helicobacter pylori antigens, typically in stool samples, serving as a direct biomarker of active infection in the gastrointestinal tract. H. pylori is a gram-negative bacterium associated with chronic gastritis, peptic ulcer disease, and gastric malignancies. The detection of its antigens reflects ongoing bacterial colonization and infection rather than past exposure, making it a useful non-invasive diagnostic alternative to endoscopic biopsy or urea breath testing. The test commonly employs enzyme immunoassay (EIA) or immunochromatographic methods that recognize specific H. pylori surface or secreted antigens.
In clinical practice, the H. pylori antigen qualitative assay is primarily used for diagnosis and post-treatment monitoring, as it allows for confirmation of eradication after antibiotic therapy. Its non-invasive nature and high specificity make it suitable for large-scale screening in both symptomatic and asymptomatic populations. In research settings, this biomarker is valuable for epidemiological studies assessing H. pylori prevalence, transmission patterns, and treatment outcomes. Additionally, it supports investigations into host-pathogen interactions and the role of H. pylori in gastric cancer risk and microbiome alterations, thereby bridging clinical diagnostics with translational and public health research.
This product is manufactured in USA by Eagle Biosciences.
| Size | 1 x 96 Well |
| Sensitivity | 0.165 ng/mL |
| Dynamic Range | 1.9 – 150 ng/mL |
| Incubation Time | 2 hours |
| Sample Type | Stool |
| Storage | 2-8°C |
| Alternative Names | Helicobacter pylori Antigen, Hp Antigen, H. pylori Stool Antigen, Helicobacter pylori Surface Antigen, and HpSA. |